Search research articles
Contact Us
Filters
Showing results (1381-1390 of 1,873) with videos related to
Page
of 188
Sort By:
JACC. Heart Failure
|
October 31, 2025
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure
James E Udelson, Jan Bělohlávek, Andrej Dukát, et al.
European Journal of Heart Failure
|
March 2, 2026
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF
Ryohei Ono, Misato Chimura, Kieran F Docherty, et al.
European Journal of Heart Failure
|
April 10, 2026
Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF
Iris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
European Journal of Heart Failure
|
May 14, 2024
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial
Muthiah Vaduganathan, Brian L Claggett, Carolyn S P Lam, et al.
American Journal of Nephrology
|
January 19, 2011
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease
Ravi Thadhani, Evan Appelbaum, Yuchiao Chang, et al.
Circulation
|
July 28, 2010
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
Anne-Catherine Pouleur, Ebrahim Barkoudah, Hajime Uno, et al.
Circulation. Heart Failure
|
May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
Journal of Diabetes Research
|
January 17, 2019
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration
Jelena P Seferovic, Rhonda Bentley-Lewis, Brian Claggett, et al.
European Heart Journal
|
August 2, 2015
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
Pardeep S Jhund, Michael Fu, Edmundo Bayram, et al.
European Journal of Heart Failure
|
November 17, 2022
Health-related quality of life outcomes in PARAGON-HF
Alvin Chandra, Carisi A Polanczyk, Brian L Claggett, et al.
Page
of 188
Search research articles
Search
Showing results (1381-1390 of 1,873) with videos related to
Sort By:
Page
of 188
JACC. Heart Failure
|
October 31, 2025
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure
James E Udelson, Jan Bělohlávek, Andrej Dukát, et al.
European Journal of Heart Failure
|
March 2, 2026
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF
Ryohei Ono, Misato Chimura, Kieran F Docherty, et al.
European Journal of Heart Failure
|
April 10, 2026
Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF
Iris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
European Journal of Heart Failure
|
May 14, 2024
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial
Muthiah Vaduganathan, Brian L Claggett, Carolyn S P Lam, et al.
American Journal of Nephrology
|
January 19, 2011
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease
Ravi Thadhani, Evan Appelbaum, Yuchiao Chang, et al.
Circulation
|
July 28, 2010
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
Anne-Catherine Pouleur, Ebrahim Barkoudah, Hajime Uno, et al.
Circulation. Heart Failure
|
May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
Journal of Diabetes Research
|
January 17, 2019
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration
Jelena P Seferovic, Rhonda Bentley-Lewis, Brian Claggett, et al.
European Heart Journal
|
August 2, 2015
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
Pardeep S Jhund, Michael Fu, Edmundo Bayram, et al.
European Journal of Heart Failure
|
November 17, 2022
Health-related quality of life outcomes in PARAGON-HF
Alvin Chandra, Carisi A Polanczyk, Brian L Claggett, et al.
Page
of 188